REG - Tristel PLC - Notice of Results

TristelAnnouncement

06/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260206:nRSF9220Ra&default-theme=true

RNS Number : 9220R  Tristel PLC  06 February 2026

TRISTEL plc

("Tristel" or the "Company")

 

Notice of Interim Results

Analyst and Investor briefing schedule

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces that it will report its interim results for the six-month period
ended 31 December 2025 on Monday 2 March 2026.

 

Analyst briefing

A briefing open to analysts will take place in London on Monday 2 March 2026
at 11.00am. To register and for more details please contact Walbrook PR
on tristel@walbrookpr.com 

 

Investor presentation

Matt Sassone, CEO, and Anna Wasyl, CFO, will present the Company's results in
two separate events open to all investors. The same presentation will be given
at both events which are being held at different times to offer convenient
options for those wishing to attend.

 

Two presentations will take place on Monday 2 March 2026 at the following
times, the first will be held online via the Investor Meet Company platform
and the second will be held in-person in the City of London, full details
below:

 

1.    Investor Meet Company online presentation

Tristel management will provide a live online presentation relating to
the interim results via Investor Meet Company at 9.30am. The presentation
is open to all existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9am the day before
the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to
meet Tristel plc via:

https://www.investormeetcompany.com/tristel-plc/register-investor
(https://www.investormeetcompany.com/tristel-plc/register-investor)

 

2.    In-person investor presentation

Tristel management will provide an in-person presentation relating to the
Company's interim results at 4.30pm, which is open to all existing and
potential shareholders. The Company welcomes investors from 4.15pm for a
4.30pm start and will be followed by refreshments.

 

If you would like to attend, please contact Walbrook PR for more details on
020 7933 8780 or email tristel@walbrookpr.com.

 

The results presentation will be made available on the Company's website on
the day of results - https://investors.tristel.com/
(https://investors.tristel.com/)

 

 

For further information please contact:

 

 Tristel plc                                                              Via Walbrook PR
 Matt Sassone, Chief Executive Officer                                    https://investors.tristel.com/ (https://investors.tristel.com/)
 Anna Wasyl, Chief Financial Officer

 Walbrook PR Ltd                                                          Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus / Lianne Applegarth / Anna Dunphy    Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

 Cavendish Capital Markets Ltd                                            Tel: 020 7220 0500
 Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance)
 Sunila de Silva (ECM) / Louise Talbot (Sales)

 

 

 

About Tristel plc

 

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/tristel/) brand, and under the Cache
(https://tristel.com/cache/) brand provides products for sporicidal surface
disinfection, a more sustainable alternative to commonly used pre-wetted
plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets delivering
double-digit revenue growth annually, an adjusted EBITDA margin of at least
25% and a continuing progressive year-on-year growth in dividends, underpinned
by robust cash generation.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUPUMUPUPQGPA



            Copyright 2019 Regulatory News Service, all rights reserved